Neoadjuvant atezolizumab plus docetaxel/oxaliplatin/capecitabine in non-metastatic gastric and gastroesophageal junction adenocarcinoma: The PANDA trial.

Yara L. Verschoor,Liudmila Kodach,Jose Van den Berg,Johanna W. Van Sandick,Jolanda Van Dieren,Sara Balduzzi,Cecile Grootscholten, Xander Veenhof,Koen Hartemink,Marieke A. Vollebergh, E. C. Owers,Annemarieke Bartels-Rutten, Peggy Den Hartog,Monique E. Van Leerdam,Ton Schumacher,Emile E. Voest,John B. A. G. Haanen,Myriam Chalabi

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 7|浏览10

暂无评分

关键词

neoadjuvant atezolizumab,gastroesophageal junction adenocarcinoma,junction adenocarcinoma,docetaxel/oxaliplatin/capecitabine,panda trial,non-metastatic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要